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To determine the role of p53 protein on the cellular effects of amifostine, we used molecularly engineered HCT116 colon cancer
cells in which the p53 gene was inactivated by targeted homologous recombination or p53 protein was degraded by high-level
expression of papillomavirus E6 protein. Amifostine induced a G1 arrest and protected against paclitaxel toxicity in p53-proficient but
not in p53-deficient cells. In the absence of p53 protein, amifostine enhanced the cytotoxicity of paclitaxel. In addition, treatment of
HCT116 cells with amifostine alone resulted in apoptotic cell death. Compared with p53-deficient cells, p53-proficient cells exhibited
low-level resistance to amifostine-induced apoptosis. Amifostine induced the expression of p53 protein in p53-proficient cells and the
expression of p21 protein in both p53-proficient and -deficient cells. These findings indicate that amifostine-induced G1 arrest and
cytoprotection are mediated via a pathway that is dependent on p53 protein and that amifostine-induced expression of p21 protein
is not sufficient to sustain a G1 arrest or to mediate cytoprotection. In addition, these findings identify p53 protein as a mechanism of
resistance to amifostine-induced apoptosis.
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Amifostine, designated WR-2721, was originally synthesised at the
Walter Reed Army Institute of Research in the 1950s to protect
military personnel from nuclear radiation. Amifostine protects
cells from cytotoxic damage by scavenging oxygen-free radicals
caused by radiation and radiomimetic drugs and by binding to
reactive nucleophiles, which have the potential to react with DNA
(van der Vijgh and Peters, 1994).
Amifostine has demonstrated broad-spectrum cytoprotection
against myelotoxicity, nephrotoxicity, xerostomia, and mucositis
associated with various chemotherapy and radiation regimens
(Capizzi and Oster, 2000). Large comparative clinical trials of
amifostine in patients with advanced ovarian cancer (Kemp et al,
1996), rectal cancer (Liu et al, 1992), and head and neck cancer
(Brizel et al, 2000) have been completed. These trials have shown
that amifostine protects against the cytotoxic effects of cisplatin,
cyclophosphamide, and radiation therapy. In addition, amifostine
protects against xerostomia in patients with head and neck cancer
treated with radiation therapy and in patients with thyroid cancer
treated with high-dose radio-iodine (Bohuslavizki et al, 1998;
Buntzel et al, 1998). Recent observations also indicate that
amifostine improves cytopenia in patients with myelodysplastic
syndromes (List et al, 1997, 1998).
WR-1065, the active metabolite of amifostine, protects cells from
cytotoxic damage by scavenging oxygen-free radicals generated by
radiation and anthracyclines and by binding to highly reactive
nucleophiles and thus preventing nucleophiles from reacting with
DNA (Treskes and van der Vijgh, 1993). The sulphydryl group of
WR-1065 inactivates carbonium ions generated by alkylating
agents and thereby prevents the formation of DNA crosslinks
(DeNeve et al, 1988). Amifostine also protects against the
cytotoxicity of paclitaxel, a cytoprotective effect that is not readily
explained (Taylor et al, 1997).
In addition to its cytoprotective properties, amifostine has other
interesting biologic effects. For instance, WR-1065 reduces the
level of phosphorylation and inhibits the enzymatic activity of
topoisomerase II (Grdina et al, 1994; Murley et al, 1997; Snyder
and Grdina, 2000). Amifostine and its metabolite upregulate genes
involved in cell proliferation, including c-myc and thymidine
kinase (Woloschak et al, 1995; Liu et al, 1997). In mouse
fibroblasts and breast cancer cells, amifostine and its metabolite
WR-1065 have been shown to activate p53 protein, to induce the
expression of the cyclin-dependent kinase inhibitor p21, and to
arrest cells at the G1/S transition via a p53-dependent pathway
(North et al, 2000). In addition, amifostine binds to the
transcription factors nuclear factor-kB, activator protein-1, and
p53 protein, resulting in enhanced binding of these proteins to
target regulatory DNA sequences and subsequent transactivation
of downstream genes (Shen et al, 2001). Similarly, in a yeast
functional assay, amifostine restored the transcriptional activity of
p53 mutants (Maurici et al, 2001). In nontransformed cells,
WR-1065 protects cells from the cytotoxic effects of paclitaxel in a
p53-dependent manner (Shen et al, 2001). However, amifostine
had no cytoprotective effect in transformed human tumour cells,
suggesting that p53-dependent growth arrest is the basis for the
protective effect of amifostine and that this pathway is abrogated
in human tumours (Shen et al, 2001).
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sIn the current study, we used two sets of p53-proficient and
-deficient cell lines to determine the effect of p53 protein on
amifostine-induced apoptosis, cell cycle arrest, and cytoprotection.
MATERIALS AND METHODS
Cell lines
Parental human colon carcinoma HCT116 cells were obtained from
the American Type Culture Collection (ATCC, CCL 247). HCT116
cells contain a hemizygous mutation in hMLH1, resulting in a
truncated, nonfunctional protein (Boyer et al, 1995). A subline
complemented with chromosome 3, designated HCT116+ch3, was
obtained from Drs CR Boland and M Koi (Koi et al, 1994). The
chromosome 3-complemented cells were competent in DNA
mismatch repair (Koi et al, 1994). HCT116 cells in which both
p53 alleles were deleted by targeted homologous recombination,
designated HCT116/p53
 / , were obtained from Dr Bert Vogel-
stein (Bunz et al, 1999). HCT116 cells and HCT116+ch3 expressing
papillomavirus E6, designated HCT116/E6 and HCT116+ch3/E6,
were obtained from Drs A Boothman and M Meyers. These cell
lines constitutively express high levels of human papillomavirus
type-16 E6 protein, which stimulates the degradation of p53
protein via an ubiquitin-dependent pathway (Davis et al, 1998). All
cell lines were maintained in Iscove’s modified Dulbecco’s medium
(Irvine Scientific, Irvine, CA, USA) supplemented with 100mML -
glutamine and 10% heat-inactivated foetal bovine serum. The
chromosome-complemented lines were grown in medium supple-
mented with 400mgml
 1 geneticine (GIBCO BRL, Gaithersburg,
MD, USA). HCT116/p53
+/+ and HCT116/p53
 /  cells were
maintained in McCoy’s medium (Irvine Scientific, Irvine, CA,
USA) supplemented with 100mML -glutamine and 10% heat-
inactivated foetal bovine serum.
Reagents
Amifostine was obtained from US Bioscience Corporation; a stock
solution of 50mgml
 1 was prepared in 0.9% NaCl and stored at
41C. Paclitaxel was obtained from Sigma Chemical Co. (St Louis,
MO, USA) and was dissolved in DMSO.
Clonogenic assay
For clonogenic assays, 500 cells were seeded in plastic dishes
containing complete media. The cells were allowed to attach
overnight, and on the next day, cells were exposed to amifostine at
increasing concentrations for 24h. Thereafter, the cells were
washed with PBS and fresh, drug-free medium was added. After
10–14 days of incubation in humidified 5% CO2 at 371C, cells were
washed, fixed with methanol, and stained with 0.1% crystal violet.
Cell clusters containing more than 50 cells were scored as a colony.
Each experiment was performed a minimum of three times using
triplicate cultures for each drug concentration. IC50 (concentration
causing 50% inhibition of cell growth) values were estimated using
log-linear interpolation.
Cell cycle phase distribution
Approximately 1 10
6–2 10
6 cells were exposed to amifostine
for 24h. At various points in time after starting amifostine
treatment, cells were harvested, washed twice with ice-cold PBS,
and fixed in ice-cold 100% ethanol. Cells were counted and 10
6
cells per sample were centrifuged, resuspended in 500ml of ice-cold
PBS, and treated with 0.1mgml
 1 RNAse A (Sigma Chemical Co.)
at 371C for 30min. Propidium iodide (Molecular Probes, Eugene,
OR, USA) at a final concentration of 50mgml
 1 was then added to
the cell suspensions. After incubation on ice for 30min, cells were
analysed on a FACScan flowcytometer (Becton-Dickinson, San
Jose, CA, USA). Multicycle AV Cell Cycle software (Phoenix Flow
Systems, San Diego, CA, USA) was used to calculate the fraction of
cells in each phase of the cell cycle as previously described (Dean
and Jett, 1974).
Quantitation of apoptotic cells
Cells were treated with amifostine for 24h. At various points in
time, floating and attached cells were harvested, centrifuged,
resuspended in 100ml of PBS, and stained with acridine orange and
ethidium bromide. Subsequently, cells were assessed for apoptotic
morphology by supravital fluorescence microscopy. Cells were
scored as apoptotic according to established morphologic criteria
(McGahon et al, 1995).
Western blot analysis
Logarithmically growing cells were treated with amifostine for 24h.
At various points in time after the beginning of exposure to
amifostine, cells were lysed and proteins extracted in a buffer
containing 0.15 M NaCl, 5mM EDTA. 1% Triton X-100, 10mM TRIS
(pH 7.4), 5mM DTT, 0.1mM phenylmethylsulphonyl fluoride, and
5m M epsilon-aminocaproic acid. Proteins were quantitated and
fractionated by electrophoresis using 7.5 and 15% polyacrylamide
gels (Precast Acrylamide Gels, Bio-Rad, Hercules, CA, USA).
Proteins were transferred to polyvinylidene difluoride membranes
(Immobilon, Millipore, Bedford, MA, USA). The membranes were
blocked with 5% nonfat milk, 0.05% Tween for 1h, washed with
0.05% Tween and then exposed to primary antibody overnight at
41C. Mouse monoclonal anti-p21 (sc-817) and anti-p53 (sc-126)
antibodies were obtained from Santa Cruz Biotechnology, Santa
Cruz, CA, USA. Primary antibodies were diluted 1:400 in 5–10%
nonfat milk. After washing, blots were exposed to horseradish
peroxidase-conjugated anti-mouse antibodies (Amersham Life
Science, Inc., Arlington Heights, IL, USA) at a dilution of
1:3000, and complexes were visualised by enhanced chemilumi-
nescence.
RESULTS
To investigate how p53 protein regulates the cellular response to
amifostine, we used p53-proficient parental HCT116/p53
+/+ and
p53-deficient HCT116/p53
 / cells, in which both p53 alleles were
deleted by homologous recombination (Davis et al, 1998). HCT116
cells are genomically instable because of a homozygous mutation
at the hMLH1 locus (Koi et al, 1994; Papadopoulos et al, 1994). As
a result, HCT116 cells have accumulated multiple mutations,
including mutations of the genes encoding the type II receptor for
transforming growth factor b 1, the insulin-like growth factor II
receptor, and the proapoptotic gene BAX (Carethers and Pham,
2000). In addition, defective expression of hMLH1 in HCT116 cells
results in alterations in the G2/M cell cycle checkpoint following
radiation (Hawn et al, 1995). In order to control for spurious
effects that are a result of genomic instability and alterations in cell
cycle progression, we also used a mismatch repair-proficient
HCT116 subline complemented with chromosome 3. HCT116+ch3
cells are genomically stable and have an intact G2/M checkpoint
following radiation (Hawn et al, 1995; Carethers and Pham, 2000).
In HCT116+ch3 cells, p53 was inactivated by constitutive high-
level expression of the human papillomavirus type 16 E6 gene,
which stimulates the degradation of p53 protein (Davis et al, 1998).
Effect of p53 protein on amifostine toxicity
Clonogenic assays were used to determine the effect of p53 protein
on the sensitivity of HCT116 colon cancer cells to amifostine
(Figure 1). After allowing cells to attach overnight, p53-proficient
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sand -deficient HCT116 cells were exposed to increasing concen-
trations of amifostine for 24h. The number of colonies was
assessed after 10–14 days. In HCT116 cells, deletion of the p53
gene by targeted homologous deletion resulted in a 1.470.2-fold
increase in amifostine sensitivity, as quantitated by the ratio of the
IC50 values (mean7s.d., n¼3, Po0.05 by a two-sided t-test).
Similarly, degradation of p53 protein by E6 resulted in a 1.670.2-
fold increase in amifostine sensitivity (mean7s.d., n¼3, Po0.05
by a two-sided t-test). In mismatch repair-proficient HCT116+ch3
cells, degradation of p53 protein by E6 resulted in a 1.970.2-fold
increase in sensitivity to amifostine (mean7s.d., n¼3, Po0.05 by
a two-sided t-test).
Effect of p53 protein on amifostine-induced apoptosis
Supravital fluorescence microscopy was used to quantitate
apoptotic cells (Figure 2). HCT116/p53
+/+, HCT116/p53
 / , and
HCT116/E6 cells were exposed to 3.8mM amifostine for 24h, a
schedule that corresponded to an IC50 in HCT116/p53
+/+ cells.
HCT116+ch3 and HCT116+ch3/E6 cells were exposed to 4.9mM
amifostine for 24h, which corresponded to an IC50 in HCT116+ch3
cells. The fraction of apoptotic cells was determined at 72 and 96h
after the beginning of exposure to amifostine. Equimolar
concentrations of amifostine are expected to result in the same
extent of cellular injury in cells that differ only with respect to p53
status. Therefore, any differential effect in amifostine-induced
apoptosis is conjectured to be the result of p53-mediated,
differential processing of cellular damage. In HCT116 cells,
deletion of the p53 gene by targeted recombination resulted in
an increase in amifostine-induced apoptosis by 1.970.2- and
1.870.2-fold at 72 and 96h after the beginning of exposure to
amifostine, respectively (mean7s.d., n¼3, Po0.05 by a two-sided
t-test for the comparison of p53-proficient vs -deficient cells).
Similarly, degradation of p53 protein by E6 resulted in an increase
in amifostine-induced apoptosis by 2.170.2-fold and 1.570.2-fold
at 72 and 96h after the beginning of exposure to amifostine,
respectively (mean7s.d., n¼3, Po0.05 by a two-sided t-test for
the comparison of p53-proficient vs -deficient cells). In mismatch
repair-proficient HCT116+ch3 cells, E6-mediated degradation of
p53 protein resulted in an increase in amifostine-induced
apoptosis by 1.870.2- and 2.070.2- at 72 and 96h, respectively
(mean7s.d., n¼3, Po0.05 by a two-sided t-test for the
comparison of p53-proficient vs -deficient cells).
Effect of p53 protein on cell cycle arrest induced by
amifostine
HCT116/p53
+/+ and HCT116/p53
 /  cells were exposed to 3.8mM
amifostine for 24h, which corresponded to an IC50 in HCT116/
p53
+/+ cells. HCT116+ch3 and HCT116+ch3/E6 cells were exposed
to 4.9mM amifostine for 24h, which corresponded to an IC50 in
HCT116+ch3 cells. In p53-proficient HCT116/p53
+/+ and
HCT116+ch3 cells, treatment with amifostine caused a G1 arrest
that peaked at 24h (Figure 3). However, in p53-deficient HCT116/
p53
 /  and HCT116+ch3/E6 cells, amifostine failed to cause a G1
arrest, indicating that the G1 arrest induced by amifostine is
dependent on p53 protein. Amifostine also caused a G2/M arrest,
which occurred in both p53-proficient and -deficient cells,
indicating that the G2/M arrest is mediated via a pathway that is
independent of p53 protein.
Effect of p53 protein on amifostine-induced cytoprotection
To determine whether p53 protein regulates the cytoprotective
properties of amifostine, we investigated the effect of amifostine on
paclitaxel toxicity in p53-proficient and -deficient cells (Figure 4).
HCT116 cells were exposed to 20nM paclitaxel for 24h in the
absence or presence of amifostine. Amifostine-treated cells were
pretreated with 100mM amifostine for 30min and subsequently
exposed to amifostine and paclitaxel for 24h. At this concentra-
tion, amifostine is nontoxic; however, even at low concentrations,
amifostine has important biologic effects, such as induction of p53
protein, a finding that occurs at concentrations as low as 50mM
(North et al, 2000). At 48h after the beginning of drug exposure,
cells were stained with acridine orange and ethidium bromide, and
the fraction of apoptotic cells was determined by supravital
fluorescence microscopy. Amifostine protected p53-proficient
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Figure 1 Effect of p53 protein on amifostine toxicity. HCT116 cells
were exposed to amifostine for 24h, and dose–response curves were
generated by clonogenic assay. Left panel: (J), HCT116/p53
+/+ cells; (K),
HCT116/p53
 /  cells; (’), HCT116/E6 cells. Right panel: (J),
HCT116+ch3 cells; (K), HCT116+ch3/E6 cells. Data points represent
mean7s.d. of at least three independent experiments performed with
triplicate cultures.
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Figure 2 Effect of p53 protein on amifostine-induced apoptosis.
HCT116 cells were exposed to amifostine for 24h, and the fraction of
apoptotic cells was determined by supravital fluorescence microscopy at 72
and 96h after the beginning of exposure to amifostine. Upper panel: white
columns, HCT116/p53
+/+ cells; black columns, HCT116/p53
 /  cells;
shaded columns, HCT116/E6 cells. Lower panel: white columns,
HCT116+ch3 cells; shaded columns, HCT116+ch3/E6 cells. Columns
and bars represent mean7s.d. of three independent experiments each
performed with triplicate cultures.
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sHCT116/p53
+/+ and HCT116+ch3 cells from the cytotoxicity of
paclitaxel and reduced paclitaxel-induced apoptosis by 1.7570.2-
fold (mean7s.d., n¼3, Po0.05 by a two-sided t-test) and
2.070.2-fold (Po0.05), respectively. However, amifostine failed
to protect p53-deficient cells from the cytotoxicity of paclitaxel,
indicating that the cytoprotective effect of amifostine is
p53-dependent. Interestingly, in p53-deficient HCT116/p53
 / 
and HCT116+ch3/E6 cells, amifostine enhanced paclitaxel-induced
apoptosis by 2.170.2-fold (mean7s.d., n¼3, Po0.05 by a two-
sided t-test) and 2.270.2-fold (Po0.05), respectively.
Effect of amifostine on the expression of p53 protein
and p21 protein
To further investigate the role of p53 protein and p21 protein on
amifostine-induced apoptosis and cell cycle progression, we
determined the effect of amifostine on the expression of p53
protein and p21 protein in p53-proficient and -deficient cells
(Figure 5). HCT116/p53
+/+ and HCT116/p53
 / cells were exposed
to 3.8mM amifostine for 24h, which corresponded to an IC50 in
HCT116/p53
+/+ cells. HCT116+ch3 and HCT116+ch3/E6 cells were
exposed to 4.9mM amifostine for 24h, corresponding to an IC50 in
HCT116+ch3 cells. In p53-proficient cells, amifostine caused a
rapid induction of p53 protein, which, like the amifostine-induced
G1 arrest, peaked at 24h.
In addition, amifostine caused a rapid induction of p21 protein.
Induction of p21 protein occurred in both p53-proficient and
-deficient cells, indicating that the induction of p21 protein in
response to amifostine is independent of p53 protein. In
p53-deficient cells, amifostine induced the expression of p21
protein without causing a G1 arrest, indicating that overexpression
of p21 protein in response to amifostine was not sufficient to arrest
cells in the G1 phase of the cell cycle.
DISCUSSION
The prodrug amifostine and its active metabolite WR-1065 have
been shown to have differential effects on malignant vs
nonmalignant tissue. For instance, amifostine protects normal
tissues from the toxic effects of ionising radiation and chemothera-
peutic agents, but has either no effect or enhances the antitumour
effects of these agents (van der Vijgh and Peters, 1994; Taylor et al,
1997; Capizzi, 1999a; Shen et al, 2001). The mechanisms by
which amifostine preferentially protects normal cells are poorly
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Figure 3 Effect of p53 protein on cell cycle arrest induced by amifostine.
HCT116 cells were exposed to amifostine for 24h and cell cycle phase
distribution was determined by flowcytometry. Data points represent
mean7s.d. of three independent experiments.
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Figure 4 Effect of p53 protein on amifostine-induced cytoprotection.
HCT116 cells were exposed to paclitaxel for 24h in the absence or
presence of amifostine. The fraction of apoptotic cells was determined by
supravital fluorescence microscopy at 48h after the beginning of drug
exposure. Open columns, cells treated with paclitaxel alone; shaded
columns, cells treated with paclitaxel and amifostine. Columns and bars
represent mean7s.d. of three independent experiments.
HCT116/p53+/+ HCT116/p53−/−
Time (h) 0 24 48 72 0 24 48 72
p21
p53 No band visible
p21
HCT116+ch3 HCT116+ch3/E6
Time (h) 0 24 48 72 0 24 48 72
p53 No band visible 
Figure 5 Effect of amifostine on the expression of p53 protein and p21
protein. HCT116 cells were exposed to amifostine for 24h and cellular
proteins were analysed by Western blotting at various points in time after
the beginning of exposure to amifostine. Amifostine induced the expression
of p53 protein in p53-proficient cells and the expression of p21 protein in
p53-proficient and -deficient cells.
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sunderstood. Selective protection of normal tissue by amifostine
has been associated with activation of a p53-dependent pathway,
and amifostine has been shown to bind to p53 protein and to
enhance transactivation of downstream genes (Shen et al, 2001).
We now report on the effects of p53 protein on the cellular
pharmacology of amifostine in two sets of matched HCT116 cell
lines that differ in p53 status. In the first set, the p53 gene was
deleted by homologous recombinant deletion; in the second set,
the p53 protein was degraded by high-level expression of human
papillomavirus E6 protein. In both sets of HCT116 cell lines,
amifostine selectively protected p53-proficient cells from the
cytotoxicity of paclitaxel. Since normal tissue is p53-proficient,
this finding could, at least in part, explain the observation that
amifostine protects normal tissues from the toxic effects of
ionising radiation and chemotherapeutic agents but fails to protect
malignant tissue, which is often p53-deficient. Many solid tumours
differ from nonmalignant tissue in that they express defective
forms of p53 protein itself or of the pathways downstream of p53
protein (Sherr and Weber, 2000).
Amifostine is a phosphorylated aminothiol prodrug that is
dephosphorylated by membrane-bound alkaline phosphatase to
form the active metabolite WR-1065, a free thiol that exhibits
cytoprotective activity after being transported into the cell (van der
Vijgh and Peters, 1994; Capizzi, 1999b). Preferential protection of
normal cells has been associated with higher activity of membrane-
bound alkaline phosphatase in normal endothelium and normal
tissue, compared to neovascular endothelium and tumour tissue
(Manheimer and Seligman, 1948; Romanul and Bannister, 1962).
However, recent observations indicate that differences in the
expression of alkaline phosphatase and cellular transport between
normal and tumour tissue cannot entirely account for the
selectivity with which amifostine protects normal tissue. For
instance, the dephosphorylated metabolite of amifostine, WR-
1065, which penetrates equally well into cultured cancer and
noncancer cells, has also been found to have a preferential
radioprotective effect on human diploid fibroblasts, as compared
to HT-1080 fibrosarcoma cells (Zhang et al, 1992).
In spite of protecting p53-proficient cells from the cytotoxicity
of paclitaxel, amifostine sensitised p53-deficient HCT116 cells to
paclitaxel. Similarly, amifostine has been shown to sensitise CaCl
melanoma cells to paclitaxel in a p53-dependent manner (Shen
et al, 2001). In addition, amifostine has been shown to protect
MRC-5 human lung fibroblasts from paclitaxel-induced cytotoxi-
city and to enhance paclitaxel cytotoxicity in A427 lung cancer
cells (Taylor et al, 1997). Although A427 cells express p53 protein
(Soini et al, 2001), these cells fail to arrest in response to DNA
damage (Strobeck et al, 2001), indicating that the p53 pathway is
inactive as a result of a defect in p53 protein itself or in a pathway
downstream of p53 protein. The mechanisms by which amifostine
enhances drug sensitivity in cells with a defective p53 pathway are
not well understood. Interestingly, in amifostine-treated A427
cells, enhanced sensitivity to paclitaxel has been associated with
increased formation of DNA single-strand breaks (Taylor et al,
1997).
In amifostine-treated cells, p53 protein also plays an important
role in regulating progression through the cell cycle. Amifostine
caused a G2 arrest in both p53-proficient and -deficient cells,
indicating that the amifostine-induced G2 arrest is independent of
p53 protein. In addition, amifostine induced the expression of p21
protein via a p53-independent pathway, a finding that is
compatible with a role of p21 protein in amifostine-induced G2
arrest. Indeed, p21 protein has been shown to inhibit phosphor-
ylation of Cdc2 and to enforce G2 arrest (Smits et al, 2000).
Amifostine also caused a G1 arrest, which, in contrast to the G2
arrest, occurred only in p53-proficient cells, indicating that the G1
arrest is dependent on p53 protein. In p53-proficient cells, both
the G1 arrest and the induction of p53 protein peaked at 24h
after the beginning of exposure to amifostine, a finding consistent
with the notion that the G1 arrest induced by amifostine is
mediated via a p53-dependent pathway. Since amifostine induced
the expression of p21 protein in both p53-proficient and -deficient
cells but caused a G1 arrest only in p53-proficient cells, induction
of p21 protein alone was not sufficient to sustain a G1 arrest
after treatment with amifostine. In addition to regulating the
transcription of the p21 gene, p53 protein has been shown to
regulate the transcription of genes encoding other downstream
proteins, including other members of the Cip/Kip family, such
as p27
Kip1 and p57
Kip2 (Shapiro and Harper, 1999). Like p21
protein, p27
Kip1 and p57
Kip2 proteins have also been shown to form
complexes with cyclin E-CDK2 and to promote CDK2 inhibition
and G1 arrest (Shapiro and Harper, 1999). Thus, the observation
that overexpression of p21 protein was not sufficient to sustain a
G1 arrest in amifostine-treated cells suggests that amifostine
induced the expression of one or more other cell cycle inhibitors
downstream of p53 protein.
In HCT116 cells, amifostine, a cytoprotective agent, also has the
potential to induce apoptosis. In the presence of p53 protein,
HCT116 cells exhibited low-level resistance to amifostine, indicat-
ing that p53 protein protected cells from amifostine-induced
apoptosis. The degree of resistance to amifostine conferred by p53
protein was modest, in the range of 1.5–2-fold, and the biologic
relevance of such relatively small degrees of resistance is poorly
understood. Amifostine triggered apoptotic cell death at concen-
trations that are only slightly above the plasma concentrations
achieved in clinical studies (Shaw et al, 1986, 1988), indicating that
this observation may have clinical relevance.
Taken together, our findings indicate that p53 protein plays an
important role in regulating the cellular response to amifostine and
identify p53 protein as a mechanism of resistance to amifostine-
induced apoptosis and as a mechanism of amifostine-induced G1
arrest and cytoprotection.
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